Zobrazeno 1 - 10
of 70
pro vyhledávání: '"Aaron C Tan"'
Autor:
Mustafa Khasraw, Susan M Chang, Amy B Heimberger, Michael Lim, John Simes, Solmaz Sahebjam, Michael Platten, Wolfgang Wick, David M Ashley, Patrick Y Wen, Aaron C Tan, Stephen J Bagley, Howard Colman, Evanthia Galanis, Alireza Mansouri, Simon Khagi, Minesh P Mehta, Vinay K Puduvalli, Scott J Antonia, Don Berry
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 9, Iss 7 (2021)
With rapid advances in our understanding of cancer, there is an expanding number of potential novel combination therapies, including novel–novel combinations. Identifying which combinations are appropriate and in which subpopulations are among the
Externí odkaz:
https://doaj.org/article/5fb3fb4dbf464e6b9e23b9714b84f3ae
Autor:
Tira J. Tan, W. X. Gladys Ang, Who-Whong Wang, Hui-Shan Chong, Sze Huey Tan, Rachael Cheong, John Whay-Kuang Chia, Nicholas L. Syn, Wai Ho Shuen, Rebecca Ba, Nivashini Kaliaperumal, Bijin Au, Richard Hopkins, Xinhua Li, Aaron C. Tan, Amanda O. L. Seet, John E. Connolly, Thaschawee Arkachaisri, Valerie Chew, Ahmad bin Mohamed Lajam, Dianyan Guo, Marvin Z. W. Chew, Martin Wasser, Pavanish Kumar, Salvatore Albani, Han Chong Toh
Publikováno v:
Nature Communications, Vol 13, Iss 1, Pp 1-11 (2022)
Ad-sig-hMUC1/ecdCD40L is a recombinant adenovirus vaccine comprising human MUC1 antigen fused to the extracellular domain of the CD40 ligand. Here the authors report the result of a phase I clinical trial of Ad-sig-hMUC1/ecdCD40L in patients with adv
Externí odkaz:
https://doaj.org/article/bc9966f3f06642699fbd9cc02be4f7e3
Autor:
Shamin Li, Summer Zhuang, Antja Heit, Si-Lin Koo, Aaron C. Tan, I-Ting Chow, William W. Kwok, Iain Beehuat Tan, Daniel S.W. Tan, Yannick Simoni, Evan W. Newell
Publikováno v:
OncoImmunology, Vol 11, Iss 1 (2022)
Tumor-specific T cells likely underpin effective immune checkpoint-blockade therapies. Yet, most studies focus on Treg cells and CD8+ tumor-infiltrating lymphocytes (TILs). Here, we study CD4+ TILs in human lung and colorectal cancers and observe tha
Externí odkaz:
https://doaj.org/article/cf73d279a12043e098c3dbbed9b3b8db
Autor:
Aaron C. Tan
Publikováno v:
Thoracic Cancer, Vol 11, Iss 3, Pp 511-518 (2020)
The traditional classification of lung cancer into small cell lung cancer and non‐small cell lung cancer (NSCLC) has been transformed with the increased understanding of the molecular alterations and genomic biomarkers that drive the development of
Externí odkaz:
https://doaj.org/article/0bde963b777c4b72a10f818249e41701
Autor:
Aaron C. Tan, Drexell H. Boggs, Eudocia Q. Lee, Michelle M. Kim, Minesh P. Mehta, Mustafa Khasraw
Publikováno v:
Frontiers in Oncology, Vol 11 (2022)
Brain metastases cause significant morbidity and mortality in patients with advanced cancer. In the era of precision oncology and immunotherapy, there are rapidly evolving systemic treatment options. These novel therapies may have variable intracrani
Externí odkaz:
https://doaj.org/article/9e7528317dd84f12b6db5692ca468206
Autor:
Jiyun Lee, MD, Aaron C. Tan, BSc, M.B.B.S., PhD, FRACP, Siqin Zhou, MSc Statistics, Shinkyo Yoon, MD, PhD, Siyang Liu, MD, PhD, Ken Masuda, MD, Hidetoshi Hayashi, MD, PhD, Ullas Batra, MD, DM, Dong-Wan Kim, MD, PhD, Yasushi Goto, MD, PhD, Sze Huey Tan, PhD, Yi-Long Wu, MD, Dae Ho Lee, MD, PhD, Daniel S.W. Tan, BSc, M.B.B.S., MRCP, PhD, Myung-Ju Ahn, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 1, Pp 100261- (2022)
Introduction: Whereas interpatient heterogeneity in clinical characteristics and treatment outcomes of NSCLC harboring a KRAS mutation is recognized, the characterization of these patients in Asia has been limited. Methods: A multicenter, retrospecti
Externí odkaz:
https://doaj.org/article/45d393969fda454f81842b5e420fbb77
Autor:
Aaron C. Tan, Nick Pavlakis
Publikováno v:
International Journal of Molecular Sciences, Vol 23, Iss 16, p 8863 (2022)
The management of advanced lung cancer has been transformed with the identification of targetable oncogenic driver alterations. This includes anaplastic lymphoma kinase (ALK) gene rearrangements. ALK tyrosine kinase inhibitors (TKI) are established f
Externí odkaz:
https://doaj.org/article/a2a2f9ef474a4f568612a7a8c7e5f93d
Autor:
Alex Broom, Leah Williams Veazey, Katherine Kenny, Imogen Harper, Michelle Peterie, Alexander Page, Nicole Cort, Jennifer Durling, Eric S. Lipp, Aaron C. Tan, Kyle M. Walsh, Brent A. Hanks, Margaret Johnson, Amanda E.D. Van Swearingen, Carey K. Anders, David M. Ashley, Mustafa Khasraw
Publikováno v:
Clinical Cancer Research. 29:1670-1677
For three years, COVID-19 has circulated among our communities and around the world, fundamentally changing social interactions, health care systems, and service delivery. For people living with (and receiving treatment for) cancer, pandemic conditio
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::96b83faf23b6dae3f0915b751a837db9
https://doi.org/10.1158/1078-0432.ccr-23-0151
https://doi.org/10.1158/1078-0432.ccr-23-0151
Publikováno v:
Expert Review of Anticancer Therapy. 23:117-120
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::253c1c35e9bf76781520b5fa869ea807
https://doi.org/10.1080/14737140.2023.2152795
https://doi.org/10.1080/14737140.2023.2152795
Autor:
Aaron C. Tan
Publikováno v:
Onco. 2:181-185
The discovery of therapeutically targetable oncogenic driver alterations has led to marked improvements in NSCLC outcomes. Targeted agents have been approved for an expanding list of biomarkers. Consequently, the accurate and timely identification of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3f5504d74ec10f1aa3905ac15f3d4163
https://doi.org/10.3390/onco2030012
https://doi.org/10.3390/onco2030012